285 related articles for article (PubMed ID: 19178897)
21. Morbidity in breast cancer patients with sentinel node metastases undergoing delayed axillary lymph node dissection (ALND) compared with immediate ALND.
Goyal A; Newcombe RG; Chhabra A; Mansel RE
Ann Surg Oncol; 2008 Jan; 15(1):262-7. PubMed ID: 17879117
[TBL] [Abstract][Full Text] [Related]
22. Low locoregional failure rates in selected breast cancer patients with tumor-positive sentinel lymph nodes who do not undergo completion axillary dissection.
Hwang RF; Gonzalez-Angulo AM; Yi M; Buchholz TA; Meric-Bernstam F; Kuerer HM; Babiera GV; Tereffe W; Liu DD; Hunt KK
Cancer; 2007 Aug; 110(4):723-30. PubMed ID: 17587208
[TBL] [Abstract][Full Text] [Related]
23. Ratio of positive to total number of sentinel nodes predicts nonsentinel node status in breast cancer patients.
Tan YY; Fan YG; Lu Y; Hwang S; Ewing C; Esserman L; Morita E; Treseler P; Leong SP
Breast J; 2005; 11(4):248-53. PubMed ID: 15982390
[TBL] [Abstract][Full Text] [Related]
24. Solitary positive sentinel lymph node accompanied by negative sentinel lymph node(s) is predictive of a negative completion axillary lymph node dissection.
Alkhatib W; Connor C; Fang F
Am J Surg; 2007 Dec; 194(6):856-8; discussion 858-9. PubMed ID: 18005784
[TBL] [Abstract][Full Text] [Related]
25. Sentinel lymph node biopsy alone has no adverse impact on the survival of patients with breast cancer.
Takei H; Suemasu K; Kurosumi M; Horii Y; Ninomiya J; Yoshida M; Hagiwara Y; Inoue K; Tabei T
Breast J; 2006; 12(5 Suppl 2):S157-64. PubMed ID: 16958996
[TBL] [Abstract][Full Text] [Related]
26. Is there any benefit from sentinel lymph node biopsy using the combined radioisotope/dye technique in breast cancer patients with clinically negative axilla?
Koukouraki S; Sanidas E; Askoxilakis J; Stathaki M; Charalambakis V; Daboudi M; Voutoufianaki I; Kafousi M; Stathopoulos E; Tsiftsis D; Karkavitsas N
Nucl Med Commun; 2009 Jan; 30(1):48-53. PubMed ID: 19020472
[TBL] [Abstract][Full Text] [Related]
27. Reoperative sentinel lymph node biopsy: a new frontier in the management of ipsilateral breast tumor recurrence.
Port ER; Garcia-Etienne CA; Park J; Fey J; Borgen PI; Cody HS
Ann Surg Oncol; 2007 Aug; 14(8):2209-14. PubMed ID: 17268882
[TBL] [Abstract][Full Text] [Related]
28. Sentinel node biopsy before neoadjuvant chemotherapy for determining axillary status and treatment prognosis in locally advanced breast cancer.
Cox CE; Cox JM; White LB; Stowell NG; Clark JD; Allred N; Meyers M; Dupont E; Furman B; Minton S
Ann Surg Oncol; 2006 Apr; 13(4):483-90. PubMed ID: 16523361
[TBL] [Abstract][Full Text] [Related]
29. Additional axillary metastases and stage migration in breast cancer patients with micrometastases or submicrometastases in sentinel lymph nodes.
van Rijk MC; Peterse JL; Nieweg OE; Oldenburg HS; Rutgers EJ; Kroon BB
Cancer; 2006 Aug; 107(3):467-71. PubMed ID: 16804924
[TBL] [Abstract][Full Text] [Related]
30. Axillary recurrence rate after tumour negative and micrometastatic positive sentinel node procedures in breast cancer patients, a population based multicenter study.
Bulte CS; van der Heiden-van der Loo M; Hennipman A
Eur J Surg Oncol; 2009 Jan; 35(1):25-31. PubMed ID: 18640809
[TBL] [Abstract][Full Text] [Related]
31. Sentinel lymph node dissection provides axillary control equal to complete axillary node dissection in breast cancer patients with lobular histology and a negative sentinel node.
Khakpour N; Hunt KK; Kuerer HM; Yi M; Meric-Bernstam F; Ross MI; Lucci A
Am J Surg; 2005 Oct; 190(4):598-601. PubMed ID: 16164930
[TBL] [Abstract][Full Text] [Related]
32. Surgical management of the axilla: do intramammary nodes matter?
Pugliese MS; Stempel MM; Cody HS; Morrow M; Gemignani ML
Am J Surg; 2009 Oct; 198(4):532-7. PubMed ID: 19800463
[TBL] [Abstract][Full Text] [Related]
33. Patients with breast cancer and negative sentinel lymph node biopsy without additional axillary lymph node dissection: a follow-up study of up to 5 years.
Domènech A; Benitez A; Bajén MT; Pla MJ; Gil M; Martín-Comín J
Oncology; 2007; 72(1-2):27-32. PubMed ID: 17998787
[TBL] [Abstract][Full Text] [Related]
34. Upstaging and improved survival of early breast cancer patients after implementation of sentinel node biopsy for axillary staging.
Vanderveen KA; Schneider PD; Khatri VP; Goodnight JE; Bold RJ
Ann Surg Oncol; 2006 Nov; 13(11):1450-6. PubMed ID: 17009150
[TBL] [Abstract][Full Text] [Related]
35. Nonsentinel node metastases in breast cancer patients with isolated tumor cells in the sentinel node: implications for completion axillary node dissection.
Calhoun KE; Hansen NM; Turner RR; Giuliano AE
Am J Surg; 2005 Oct; 190(4):588-91. PubMed ID: 16164927
[TBL] [Abstract][Full Text] [Related]
36. Axillary recurrence after negative sentinel lymph node biopsy: frequency and factors influencing recurrence on the long term.
Sanli I; Lemaire BM; Muller AJ; van Kleffens HJ; Van Poll-Franse LV; van Dijk M
Breast J; 2009; 15(3):236-41. PubMed ID: 19645777
[TBL] [Abstract][Full Text] [Related]
37. Survival outcomes in node-negative breast cancer patients evaluated with complete axillary node dissection versus sentinel lymph node biopsy.
Cox C; White L; Allred N; Meyers M; Dickson D; Dupont E; Cantor A; Ly Q; Dessureault S; King J; Nicosia S; Vrcel V; Diaz N
Ann Surg Oncol; 2006 May; 13(5):708-11. PubMed ID: 16538416
[TBL] [Abstract][Full Text] [Related]
38. Predictors to assess non-sentinel lymph node status in breast cancer patients with sentinel lymph node metastasis.
Jinno H; Sakata M; Asaga S; Wada M; Shimada T; Kitagawa Y; Suzuki T; Nakahara T; Kitamura N; Kubo A; Mukai M; Ikeda T; Kitajima M
Breast J; 2008; 14(6):551-5. PubMed ID: 19000054
[TBL] [Abstract][Full Text] [Related]
39. Validation and limitations of use of a breast cancer nomogram predicting the likelihood of non-sentinel node involvement after positive sentinel node biopsy.
Alran S; De Rycke Y; Fourchotte V; Charitansky H; Laki F; Falcou MC; Benamor M; Freneaux P; Salmon RJ; ; Sigal-Zafrani B
Ann Surg Oncol; 2007 Aug; 14(8):2195-201. PubMed ID: 17294071
[TBL] [Abstract][Full Text] [Related]
40. Sentinel lymph node biopsy after neoadjuvant chemotherapy is accurate in breast cancer patients with a clinically negative axillary nodal status at presentation.
Gimbergues P; Abrial C; Durando X; Le Bouedec G; Cachin F; Penault-Llorca F; Mouret-Reynier MA; Kwiatkowski F; Maublant J; Tchirkov A; Dauplat J
Ann Surg Oncol; 2008 May; 15(5):1316-21. PubMed ID: 18311507
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
